ID   FAAH1_HUMAN             Reviewed;         579 AA.
AC   O00519; D3DQ19; Q52M86; Q5TDF8;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2005, sequence version 2.
DT   12-APR-2017, entry version 151.
DE   RecName: Full=Fatty-acid amide hydrolase 1;
DE            EC=3.5.1.99;
DE   AltName: Full=Anandamide amidohydrolase 1;
DE   AltName: Full=Oleamide hydrolase 1;
GN   Name=FAAH; Synonyms=FAAH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=9122178; DOI=10.1073/pnas.94.6.2238;
RA   Giang D.K., Cravatt B.F.;
RT   "Molecular characterization of human and mouse fatty acid amide
RT   hydrolases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:2238-2242(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9878243; DOI=10.1006/geno.1998.5597;
RA   Wan M., Cravatt B.F., Ring H.Z., Zhang X., Francke U.;
RT   "Conserved chromosomal location and genomic structure of human and
RT   mouse fatty-acid amide hydrolase genes and evaluation of clasper as a
RT   candidate neurological mutation.";
RL   Genomics 54:408-414(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT THR-129.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT THR-129.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 456-463.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, ENZYME REGULATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=17015445; DOI=10.1074/jbc.M606646200;
RA   Wei B.Q., Mikkelsen T.S., McKinney M.K., Lander E.S., Cravatt B.F.;
RT   "A second fatty acid amide hydrolase with variable distribution among
RT   placental mammals.";
RL   J. Biol. Chem. 281:36569-36578(2006).
RN   [9]
RP   POLYMORPHISM, ASSOCIATION OF VARIANT THR-129 WITH SUSCEPTIBILITY TO
RP   POLYSUBSTANCE ABUSE, AND CHARACTERIZATION OF VARIANT THR-129.
RX   PubMed=12060782; DOI=10.1073/pnas.082235799;
RA   Sipe J.C., Chiang K., Gerber A.L., Beutler E., Cravatt B.F.;
RT   "A missense mutation in human fatty acid amide hydrolase associated
RT   with problem drug use.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:8394-8399(2002).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   CHARACTERIZATION OF VARIANT THR-129.
RX   PubMed=15254019; DOI=10.1093/hmg/ddh216;
RA   Chiang K.P., Gerber A.L., Sipe J.C., Cravatt B.F.;
RT   "Reduced cellular expression and activity of the P129T mutant of human
RT   fatty acid amide hydrolase: evidence for a link between defects in the
RT   endocannabinoid system and problem drug use.";
RL   Hum. Mol. Genet. 13:2113-2119(2004).
RN   [12]
RP   ASSOCIATION OF VARIANT THR-129 WITH SUSCEPTIBILITY TO POLYSUBSTANCE
RP   ABUSE.
RX   PubMed=16972078; DOI=10.1007/s00439-006-0250-x;
RA   Flanagan J.M., Gerber A.L., Cadet J.L., Beutler E., Sipe J.C.;
RT   "The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype
RT   analysis of an ancient missense mutation and validation of risk for
RT   drug addiction.";
RL   Hum. Genet. 120:581-588(2006).
RN   [13]
RP   VARIANT [LARGE SCALE ANALYSIS] ASP-345.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [14]
RP   ASSOCIATION OF VARIANT THR-129 WITH SUSCEPTIBILITY TO METHAMPHETAMINE
RP   DEPENDENCE.
RX   PubMed=23556448; DOI=10.2217/pgs.13.25;
RA   Sim M.S., Hatim A., Reynolds G.P., Mohamed Z.;
RT   "Association of a functional FAAH polymorphism with methamphetamine-
RT   induced symptoms and dependence in a Malaysian population.";
RL   Pharmacogenomics 14:505-514(2013).
CC   -!- FUNCTION: Degrades bioactive fatty acid amides like oleamide, the
CC       endogenous cannabinoid, anandamide and myristic amide to their
CC       corresponding acids, thereby serving to terminate the signaling
CC       functions of these molecules. Hydrolyzes polyunsaturated substrate
CC       anandamide preferentially as compared to monounsaturated
CC       substrates. {ECO:0000269|PubMed:17015445}.
CC   -!- CATALYTIC ACTIVITY: Anandamide + H(2)O = arachidonic acid +
CC       ethanolamine.
CC   -!- CATALYTIC ACTIVITY: Oleamide + H(2)O = oleic acid + NH(3).
CC   -!- ENZYME REGULATION: Inhibited by O-aryl carbamates and alpha-keto
CC       heterocytes. {ECO:0000269|PubMed:17015445}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-1389829, EBI-945833;
CC   -!- SUBCELLULAR LOCATION: Endomembrane system
CC       {ECO:0000269|PubMed:17015445}; Single-pass membrane protein
CC       {ECO:0000269|PubMed:17015445}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:17015445}. Note=Seems to be attached to
CC       intracellular membranes and a portion of the cytoskeletal network.
CC   -!- TISSUE SPECIFICITY: Highly expressed in the brain, small
CC       intestine, pancreas, skeletal muscle and testis. Also expressed in
CC       the kidney, liver, lung, placenta and prostate.
CC       {ECO:0000269|PubMed:17015445}.
CC   -!- POLYMORPHISM: Genetic variations in FAAH can be associated with
CC       susceptibility to polysubstance abuse [MIM:606581]. At
CC       homozygosity, variant Thr-129 is strongly associated with drug and
CC       alcohol abuse, and methamphetamine dependence.
CC       {ECO:0000269|PubMed:12060782, ECO:0000269|PubMed:16972078,
CC       ECO:0000269|PubMed:23556448}.
CC   -!- SIMILARITY: Belongs to the amidase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/faah/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U82535; AAB58505.1; -; mRNA.
DR   EMBL; AF098019; AAD13768.1; -; Genomic_DNA.
DR   EMBL; AF098010; AAD13768.1; JOINED; Genomic_DNA.
DR   EMBL; AF098011; AAD13768.1; JOINED; Genomic_DNA.
DR   EMBL; AF098012; AAD13768.1; JOINED; Genomic_DNA.
DR   EMBL; AF098013; AAD13768.1; JOINED; Genomic_DNA.
DR   EMBL; AF098014; AAD13768.1; JOINED; Genomic_DNA.
DR   EMBL; AF098015; AAD13768.1; JOINED; Genomic_DNA.
DR   EMBL; AF098016; AAD13768.1; JOINED; Genomic_DNA.
DR   EMBL; AF098017; AAD13768.1; JOINED; Genomic_DNA.
DR   EMBL; AF098018; AAD13768.1; JOINED; Genomic_DNA.
DR   EMBL; AY842444; AAV88095.1; -; Genomic_DNA.
DR   EMBL; AL122001; CAI21960.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06912.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06919.1; -; Genomic_DNA.
DR   EMBL; BC093632; AAH93632.1; -; mRNA.
DR   EMBL; BC110404; AAI10405.1; -; mRNA.
DR   EMBL; BC111941; AAI11942.1; -; mRNA.
DR   CCDS; CCDS535.1; -.
DR   RefSeq; NP_001432.2; NM_001441.2.
DR   UniGene; Hs.720143; -.
DR   ProteinModelPortal; O00519; -.
DR   SMR; O00519; -.
DR   BioGrid; 108464; 2.
DR   IntAct; O00519; 3.
DR   STRING; 9606.ENSP00000243167; -.
DR   BindingDB; O00519; -.
DR   ChEMBL; CHEMBL2243; -.
DR   DrugBank; DB06894; 1-DODECANOL.
DR   DrugBank; DB08400; 4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzyl)piperidine-1-carboxylic acid.
DR   DrugBank; DB08385; 4-(quinolin-3-ylmethyl)piperidine-1-carboxylic acid.
DR   DrugBank; DB00316; Acetaminophen.
DR   DrugBank; DB02465; Methoxy arachidonyl fluorophosphonate.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB00599; Thiopental.
DR   GuidetoPHARMACOLOGY; 1400; -.
DR   SwissLipids; SLP:000000145; -.
DR   iPTMnet; O00519; -.
DR   PhosphoSitePlus; O00519; -.
DR   BioMuta; FAAH; -.
DR   EPD; O00519; -.
DR   MaxQB; O00519; -.
DR   PaxDb; O00519; -.
DR   PeptideAtlas; O00519; -.
DR   PRIDE; O00519; -.
DR   Ensembl; ENST00000243167; ENSP00000243167; ENSG00000117480.
DR   GeneID; 2166; -.
DR   KEGG; hsa:2166; -.
DR   UCSC; uc001cpu.3; human.
DR   CTD; 2166; -.
DR   DisGeNET; 2166; -.
DR   GeneCards; FAAH; -.
DR   H-InvDB; HIX0000550; -.
DR   HGNC; HGNC:3553; FAAH.
DR   HPA; HPA007425; -.
DR   MalaCards; FAAH; -.
DR   MIM; 602935; gene.
DR   MIM; 606581; phenotype.
DR   neXtProt; NX_O00519; -.
DR   OpenTargets; ENSG00000117480; -.
DR   PharmGKB; PA27955; -.
DR   eggNOG; KOG1212; Eukaryota.
DR   eggNOG; COG0154; LUCA.
DR   GeneTree; ENSGT00550000074673; -.
DR   HOGENOM; HOG000016500; -.
DR   HOVERGEN; HBG005632; -.
DR   InParanoid; O00519; -.
DR   KO; K15528; -.
DR   OMA; NKETNCV; -.
DR   OrthoDB; EOG091G05JU; -.
DR   PhylomeDB; O00519; -.
DR   TreeFam; TF314455; -.
DR   BioCyc; MetaCyc:HS04139-MONOMER; -.
DR   BRENDA; 3.5.1.4; 2681.
DR   BRENDA; 3.5.1.99; 2681.
DR   Reactome; R-HSA-2142753; Arachidonic acid metabolism.
DR   SIGNOR; O00519; -.
DR   ChiTaRS; FAAH; human.
DR   GenomeRNAi; 2166; -.
DR   PRO; PR:O00519; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000117480; -.
DR   ExpressionAtlas; O00519; baseline and differential.
DR   Genevisible; O00519; HS.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031090; C:organelle membrane; ISS:UniProtKB.
DR   GO; GO:0047372; F:acylglycerol lipase activity; IEA:Ensembl.
DR   GO; GO:0004040; F:amidase activity; IEA:InterPro.
DR   GO; GO:0103073; F:anandamide amidohydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0017064; F:fatty acid amide hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0102077; F:oleamide hydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0019369; P:arachidonic acid metabolic process; TAS:Reactome.
DR   GO; GO:0009062; P:fatty acid catabolic process; IDA:UniProtKB.
DR   Gene3D; 3.90.1300.10; -; 1.
DR   InterPro; IPR000120; Amidase.
DR   InterPro; IPR020556; Amidase_CS.
DR   InterPro; IPR023631; Amidase_dom.
DR   InterPro; IPR030560; FAAH.
DR   PANTHER; PTHR11895; PTHR11895; 1.
DR   PANTHER; PTHR11895:SF121; PTHR11895:SF121; 1.
DR   Pfam; PF01425; Amidase; 1.
DR   SUPFAM; SSF75304; SSF75304; 1.
DR   PROSITE; PS00571; AMIDASES; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Direct protein sequencing;
KW   Hydrolase; Membrane; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN         1    579       Fatty-acid amide hydrolase 1.
FT                                /FTId=PRO_0000105264.
FT   TRANSMEM      9     29       Helical. {ECO:0000255}.
FT   TOPO_DOM     30    403       Cytoplasmic. {ECO:0000250}.
FT   INTRAMEM    404    433       {ECO:0000250}.
FT   TOPO_DOM    434    579       Cytoplasmic. {ECO:0000250}.
FT   REGION      238    241       Substrate binding. {ECO:0000250}.
FT   ACT_SITE    142    142       Charge relay system. {ECO:0000250}.
FT   ACT_SITE    217    217       Charge relay system. {ECO:0000250}.
FT   ACT_SITE    241    241       Acyl-ester intermediate. {ECO:0000250}.
FT   BINDING     191    191       Substrate; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   BINDING     217    217       Substrate. {ECO:0000250}.
FT   MOD_RES     241    241       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VARIANT     129    129       P -> T (polymorphism associated with
FT                                susceptibility to drug abuse; the mutant
FT                                enzyme is more sensitive to proteolytic
FT                                degradation; displays reduced cellular
FT                                expression probably due to a post-
FT                                translational mechanism preceding
FT                                productive folding; dbSNP:rs324420).
FT                                {ECO:0000269|PubMed:12060782,
FT                                ECO:0000269|PubMed:15254019,
FT                                ECO:0000269|PubMed:16972078,
FT                                ECO:0000269|PubMed:23556448,
FT                                ECO:0000269|Ref.3, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_013563.
FT   VARIANT     345    345       A -> D (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs772931153).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035704.
FT   CONFLICT     47     47       R -> K (in Ref. 1; AAB58505 and 2;
FT                                AAD13768). {ECO:0000305}.
SQ   SEQUENCE   579 AA;  63066 MW;  633A92DC36940C18 CRC64;
     MVQYELWAAL PGASGVALAC CFVAAAVALR WSGRRTARGA VVRARQRQRA GLENMDRAAQ
     RFRLQNPDLD SEALLALPLP QLVQKLHSRE LAPEAVLFTY VGKAWEVNKG TNCVTSYLAD
     CETQLSQAPR QGLLYGVPVS LKECFTYKGQ DSTLGLSLNE GVPAECDSVV VHVLKLQGAV
     PFVHTNVPQS MFSYDCSNPL FGQTVNPWKS SKSPGGSSGG EGALIGSGGS PLGLGTDIGG
     SIRFPSSFCG ICGLKPTGNR LSKSGLKGCV YGQEAVRLSV GPMARDVESL ALCLRALLCE
     DMFRLDPTVP PLPFREEVYT SSQPLRVGYY ETDNYTMPSP AMRRAVLETK QSLEAAGHTL
     VPFLPSNIPH ALETLSTGGL FSDGGHTFLQ NFKGDFVDPC LGDLVSILKL PQWLKGLLAF
     LVKPLLPRLS AFLSNMKSRS AGKLWELQHE IEVYRKTVIA QWRALDLDVV LTPMLAPALD
     LNAPGRATGA VSYTMLYNCL DFPAGVVPVT TVTAEDEAQM EHYRGYFGDI WDKMLQKGMK
     KSVGLPVAVQ CVALPWQEEL CLRFMREVER LMTPEKQSS
//
